Thomas Van Groen

Dr. Thomas Van Groen


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Neurobiology of Disease
Verified
Journal Article
Closed access
TGThomas Van Groen
Thomas Van Groen
AKAmanda J. Kiliaan
Amanda J. Kiliaan
IKInga Kadish
Inga Kadish

4 February 2009 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
TGThomas Van Groen
Thomas Van Groen
IKInga Kadish
Inga Kadish
KWKatja Wiesehan
Katja Wiesehan
SFSusanne A. Funke
Susanne A. Funke
DWDieter Willbold
Dieter Willbold

1 September 2011 in Neurobiology of Aging
Verified
Journal Article
Closed access
TGThomas Van Groen
Thomas Van Groen
IKInga Kadish
Inga Kadish
NPNatalija Popović
Natalija Popović
Miroljub PopovicMiroljub Popovic
Miroljub Popovic
MCMaría Caballero-Bleda
María Caballero-Bleda
JMJuan Antonio Madrid
Juan Antonio Madrid

24 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TGThomas Van Groen
Thomas Van Groen
SSSarah Schemmert
Sarah Schemmert
OBOleksandr Brener
Oleksandr Brener
LGLothar Gremer
Lothar Gremer
TZTamar Ziehm
Tamar Ziehm
DWDieter Willbold
Dieter Willbold
While amyloid-β protein (Aβ) aggregation into insoluble plaques is one of the pathological hallmarks of Alzheimer’s disease (AD), soluble oligomeric Aβ has been hypothesized to be responsible for synapse damage, neurodegeneration, learning, and memory deficits in AD. Here, we investigate the in vitro and in vivo efficacy of the d-enantiomeric peptide RD2, a rationally designed derivative of the previously described lead compound D3, which has been developed to efficiently eliminate toxic Aβ42 oligomers as a promising treatment strategy for AD. Besides the detailed in vitro characterization of RD2, we also report the results of a treatment study of APP/PS1 mice with RD2. After 28 days of treatment we observed enhancement of cognition and learning behaviour. Analysis on brain plaque load did not reveal significant changes, but a significant reduction of insoluble Aβ42. Our findings demonstrate that RD2 was significantly more efficient in Aβ oligomer elimination in vitro compared to D3. Enhanced cognition without reduction of plaque pathology in parallel suggests that synaptic malfunction due to Aβ oligomers rather than plaque pathology is decisive for disease development and progression. Thus, Aβ oligomer elimination by RD2 treatment may be also beneficial for AD patients.

15 November 2005 in Journal of Neuroinflammation
Verified
Journal Article
Open access
JHJari Huuskonen
Jari Huuskonen
TSTiina Suuronen
Tiina Suuronen
RMRiitta Miettinen
Riitta Miettinen
TGThomas Van Groen
Thomas Van Groen
ASAntero Salminen
Antero Salminen
Background: Propagated tissue degeneration, especially during aging, has been shown to be enhanced through potentiation of innate immune responses. Neurodegenerative diseases and a wide variety of inflammatory conditions are linked together and several anti-inflammatory compounds considered as having therapeutic potential for example in Alzheimer's disease (AD). In vitro brain slice techniques have been widely used to unravel the complexity of neuroinflammation, but rarely, has the power of the model itself been reported. Our aim was to gain a more detailed insight and understanding of the behaviour of hippocampus tissue slices in serum-free, interface culture per se and after exposure to different pro- and anti-inflammatory compounds. Methods: The responses of the slices to pro- and anti-inflammatory stimuli were monitored at various time points by measuring the leakage of lactate dehydrogenase (LDH) and the release of cytokines interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α) and nitric oxide (NO) from the culture media. Histological methods were applied to reveal the morphological status after exposure to stimuli and during the time course of the culture period. Statistical power analysis were made with nQuery Advisor®, version 5.0, (Statistical Solutions, Saugus, MA) computer program for Wilcoxon (Mann-Whitney) rank-sum test. Results: By using the interface membrane culture technique, the hippocampal slices largely recover from the trauma caused by cutting after 4–5 days in vitro. Furthermore, the cultures remain stable and retain their responsiveness to inflammatory stimuli for at least 3 weeks. During this time period, cultures are susceptible to modification by inflammatory stimuli as assessed by quantitative biochemical assays and morphological characterizations. Conclusion: The present report outlines the techniques for studying immune responses using a serum-free slice culture model. Statistically powerful data under controlled culture conditions and with ethically justified use of animals can be obtained as soon as after 4–5 DIV. The model is most probably suitable also for studies of chronic inflammation.

4 March 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
TGThomas Van Groen
Thomas Van Groen
IKInga Kadish
Inga Kadish
SFSusanne Aileen Funke
Susanne Aileen Funke
DBDirk Bartnik
Dirk Bartnik
DWDieter Willbold
Dieter Willbold
One of the characteristic pathological hallmarks of Alzheimer's disease (AD) is neuritic plaques. The sequence of events leading to deposition of amyloid-β (Aβ) peptides in plaques is not clear. Here we investigate the effects of D3, an Aβ oligomer d